Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 1
Submit an article Journal homepage
253
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer

Athanasios Dellis1st University Department of Urology, University of Athens, Aretaion Hospital, Athens, Greece
&
Athanasios Papatsoris2nd Univeristy Deparment of Urology, University of Athens, Sismanoglio General Hospital, Athens, GreeceCorrespondence[email protected]
Pages 5-10 | Published online: 08 Jan 2016

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Alison Stopeck, Adam Brufsky, Lisa Kennedy, Sumi Bhatta, Debajyoti Bhowmik, Jacqueline Buchanan, Nicolas Despiegel & Guy Hechmati. (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 23:1, pages 37-47.
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, Michele Intorcia & Guy Hechmati. (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 21:5, pages 525-536.
Read now

Articles from other publishers (3)

Jessica Y. Matuoka, James G. Kahn & Silvia R. Secoli. (2018) Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics 20:4, pages 487-499.
Crossref
Alberto Russi, Vera Damuzzo, Marta Serena, Frida Gorreja & Angelo C. Palozzo. (2016) Improving the Management of High Cost Anticancer Drugs in a Health Care System. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:3, pages grhta.5000243.
Crossref
Fengxia Chen & Feifei Pu. (2016) Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. Oncology Research and Treatment 39:7-8, pages 453-459.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.